• Je něco špatně v tomto záznamu ?

FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging

J. Krell-Roesch, H. Ruider, VJ. Lowe, GB. Stokin, A. Pink, RO. Roberts, MM. Mielke, DS. Knopman, TJ. Christianson, MM. Machulda, CR. Jack, RC. Petersen, YE. Geda,

. 2016 ; 53 (4) : 1609-16.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011107

One of the key research agenda of the field of aging is investigation of presymptomatic Alzheimer's disease (AD). Furthermore, abnormalities in brain glucose metabolism (as measured by FDG-PET) have been reported among cognitively normal elderly persons. However, little is known about the association of FDG-PET abnormalities with neuropsychiatric symptoms (NPS) in a population-based setting. Thus, we conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging in order to examine the association between brain glucose metabolism and NPS among cognitively normal (CN) persons aged > 70 years. Participants underwent FDG-PET and completed the Neuropsychiatric Inventory Questionnaire (NPI-Q), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Cognitive classification was made by an expert consensus panel. We conducted multivariable logistic regression analyses to compute odds ratios (OR) and 95% confidence intervals after adjusting for age, sex, and education. For continuous variables, we used linear regression and Spearman rank-order correlations. Of 668 CN participants (median 78.1 years, 55.4% males), 205 had an abnormal FDG-PET (i.e., standardized uptake value ratio < 1.32 in AD-related regions). Abnormal FDG-PET was associated with depression as measured by NPI-Q (OR = 2.12; 1.23-3.64); the point estimate was further elevated for APOE ɛ4 carriers (OR = 2.59; 1.00-6.69), though marginally significant. Additionally, we observed a significant association between abnormal FDG-PET and depressive and anxiety symptoms when treated as continuous measures. These findings indicate that NPS, even in community-based samples, can be an important additional tool to the biomarker-based investigation of presymptomatic AD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011107
003      
CZ-PrNML
005      
20180404142543.0
007      
ta
008      
180404s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.3233/JAD-160326 $2 doi
035    __
$a (PubMed)27447426
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Krell-Roesch, Janina $u Mayo Clinic Translational Neuroscience and Aging Program, Mayo Clinic, Scottsdale, AZ, USA.
245    10
$a FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging / $c J. Krell-Roesch, H. Ruider, VJ. Lowe, GB. Stokin, A. Pink, RO. Roberts, MM. Mielke, DS. Knopman, TJ. Christianson, MM. Machulda, CR. Jack, RC. Petersen, YE. Geda,
520    9_
$a One of the key research agenda of the field of aging is investigation of presymptomatic Alzheimer's disease (AD). Furthermore, abnormalities in brain glucose metabolism (as measured by FDG-PET) have been reported among cognitively normal elderly persons. However, little is known about the association of FDG-PET abnormalities with neuropsychiatric symptoms (NPS) in a population-based setting. Thus, we conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging in order to examine the association between brain glucose metabolism and NPS among cognitively normal (CN) persons aged > 70 years. Participants underwent FDG-PET and completed the Neuropsychiatric Inventory Questionnaire (NPI-Q), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Cognitive classification was made by an expert consensus panel. We conducted multivariable logistic regression analyses to compute odds ratios (OR) and 95% confidence intervals after adjusting for age, sex, and education. For continuous variables, we used linear regression and Spearman rank-order correlations. Of 668 CN participants (median 78.1 years, 55.4% males), 205 had an abnormal FDG-PET (i.e., standardized uptake value ratio < 1.32 in AD-related regions). Abnormal FDG-PET was associated with depression as measured by NPI-Q (OR = 2.12; 1.23-3.64); the point estimate was further elevated for APOE ɛ4 carriers (OR = 2.59; 1.00-6.69), though marginally significant. Additionally, we observed a significant association between abnormal FDG-PET and depressive and anxiety symptoms when treated as continuous measures. These findings indicate that NPS, even in community-based samples, can be an important additional tool to the biomarker-based investigation of presymptomatic AD.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a stárnutí $7 D000375
650    12
$a úzkost $x diagnostické zobrazování $x patofyziologie $x psychologie $7 D001007
650    _2
$a apolipoproteiny E $x genetika $7 D001057
650    _2
$a mozek $x diagnostické zobrazování $7 D001921
650    _2
$a kognice $x fyziologie $7 D003071
650    _2
$a kognitivní dysfunkce $x komplikace $7 D060825
650    _2
$a průřezové studie $7 D003430
650    _2
$a deprese $x diagnostické zobrazování $x patofyziologie $7 D003863
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluorodeoxyglukosa F18 $x metabolismus $7 D019788
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neuropsychologické testy $7 D009483
650    _2
$a pozitronová emisní tomografie $7 D049268
650    _2
$a psychiatrické posuzovací škály $7 D011569
650    12
$a psychomotorický neklid $x diagnostické zobrazování $x patofyziologie $x psychologie $7 D011595
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Ruider, Hanna
700    1_
$a Lowe, Val J $u Department of Radiology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Stokin, Gorazd B $u International Clinical Research Center, Brno, Czech Republic.
700    1_
$a Pink, Anna $u Mayo Clinic Translational Neuroscience and Aging Program, Mayo Clinic, Scottsdale, AZ, USA.
700    1_
$a Roberts, Rosebud O $u Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Department of Neurology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Mielke, Michelle M $u Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Knopman, David S $u Department of Neurology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Christianson, Teresa J $u Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Machulda, Mary M $u Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Jack, Clifford R $u Department of Radiology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Petersen, Ronald C $u Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Department of Neurology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Geda, Yonas E $u Mayo Clinic Translational Neuroscience and Aging Program, Mayo Clinic, Scottsdale, AZ, USA. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Department of Psychiatry & Psychology, Mayo Clinic, Scottsdale, AZ, USA. Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA.
773    0_
$w MED00006350 $t Journal of Alzheimer's disease JAD $x 1875-8908 $g Roč. 53, č. 4 (2016), s. 1609-16
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27447426 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404142623 $b ABA008
999    __
$a ok $b bmc $g 1288592 $s 1007919
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 53 $c 4 $d 1609-16 $i 1875-8908 $m Journal of Alzheimer's disease $n J Alzheimers Dis $x MED00006350
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace